Devices, systems and methods for enclosing an anatomical opening

Information

  • Patent Grant
  • 10426487
  • Patent Number
    10,426,487
  • Date Filed
    Tuesday, April 25, 2017
    7 years ago
  • Date Issued
    Tuesday, October 1, 2019
    5 years ago
Abstract
The present technology is directed generally to devices, systems, and methods for enclosing anatomical openings. In several embodiments, an aneurysm device is endovascularly deliverable to a site proximate to an arterial aneurysm. The aneurysm device includes a closure structure having a distal-facing aspect configured to at least partially occlude the aneurysm and a proximal-facing aspect configured to arch over lumina of an artery. The device further includes a supplemental stabilizer connected to the closure structure and configured to reside in the artery and press outward against a luminal wall thereof. In some embodiments, the device can also include a barrier spanning at least a portion of the distal-facing aspect of the closure structure and configured to further occlude a neck of the aneurysm. In further embodiments, the closure structure can be configured to restrict and/or divert flow to or from the aneurysm.
Description
TECHNICAL FIELD

The present technology relates to implantable therapeutic devices and methods for endovascular placement of devices at a target site, such as an opening at a neck of an aneurysm.


BACKGROUND

Many of the currently available surgical approaches for closing openings and repairing defects in anatomical lumens and tissues (e.g., blood vessels), septal defects, and other types of anatomical irregularities and defects are highly invasive. Surgical methods for clipping brain aneurysms, for example, require opening the skull, cutting or removing overlying brain tissue, clipping and repairing the aneurysm from outside the blood vessel, and then reassembling tissue and closing the skull. Surgical techniques for repairing septal defects are also highly invasive. The risks related to anesthesia, bleeding, and infection associated with these types of procedures are high, and tissue that is affected during the procedure may or may not survive and continue functioning.


Minimally invasive surgical techniques have been developed to place occlusive devices within or across an opening or cavity in the body, such as in the vasculature, spinal column, fallopian tubes, bile ducts, bronchial and other air passageways, and the like. In general, an implantable device is guided along a delivery catheter and through a distal opening of the catheter using a pusher or delivery wire to deploy the device at a target site in the vasculature. Once the occlusive device has been deployed at the target site, it is detached from the pusher mechanism without disturbing placement of the occlusive device or damaging surrounding structures.


Minimally invasive techniques are also highly desirable for treating aneurysms. In general, the minimally invasive therapeutic objective is to prevent material that collects or forms in the cavity from entering the bloodstream and to prevent blood from entering and collecting in the aneurysm. This is often accomplished by introducing various materials and devices into the aneurysm. One class of embolic agents includes injectable fluids or suspensions, such as microfibrillar collagen, various polymeric beads, and polyvinylalcohol foam. Polymeric agents may also be cross-linked to extend their stability at the vascular site. These agents are typically deposited at a target site in the vasculature using a catheter to form a solid space-filling mass. Although some of these agents provide for excellent short-term occlusion, many are thought to allow vessel recanalization due to their absorption into the blood. Other materials, such as hog hair and suspensions of metal particles, have also been proposed and used to promote occlusion of aneurysms. Polymer resins, such as cyanoacrylates, are also employed as injectable vaso-occlusive materials. These resins are typically mixed with a radiopaque contrast material or are made radiopaque by the addition of a tantalum powder. Accurate and timely placement of these mixtures is crucial and very difficult because it is difficult or impossible to control them once they have been placed in the blood flow.


Implantable vaso-occlusive metallic structures are also well known and commonly used. Many conventional vaso-occlusive devices have helical coils constructed from a shape memory material or noble metal that forms a desired coil configuration upon exiting the distal end of a delivery catheter. The function of the coil is to fill the space formed by an anatomical defect and to facilitate the formation of an embolus with the associated allied tissue. Multiple coils of the same or different structures may be implanted serially in a single aneurysm or other vessel defect during a procedure. Implantable framework structures are also used in an attempt to stabilize the wall of the aneurysm or defect prior to insertion of filling material such as coils.


Techniques for delivering conventional metallic vaso-occlusive devices to a target site generally involve a delivery catheter and a detachment mechanism that detaches the devices, such as a coil, from a delivery mechanism after placement at the target site. For example, a microcatheter can be initially steered through the delivery catheter into or adjacent to the entrance of an aneurysm either with or without a steerable guidewire. If a guidewire is used, it is then withdrawn from the microcatheter lumen and replaced by the implantable vaso-occlusive coil. The vaso-occlusive coil is advanced through and out of the microcatheter and thus deposited within the aneurysm or other vessel abnormality. It is crucial to accurately implant such vaso-occlusive devices within the internal volume of a cavity and to maintain the device within the internal volume of the aneurysm. Migration or projection of a vaso-occlusive device from the cavity may interfere with blood flow or nearby physiological structures and poses a serious health risk.


In addition to the difficulties of delivering implantable occlusion devices, some types of aneurysms are challenging to treat because of structural features of the aneurysm or because of particularities of the site. Wide-neck aneurysms, for example, are known to present particular difficulty in the placement and retention of vaso-occlusive coils. Aneurysms at sites of vascular bifurcation are another example where the anatomical structure poses challenges to methods and devices that are effective in treating the typical sidewall aneurysms.


In view of such challenges, implanting conventional embolic coils, other structures, or materials in the internal space of an aneurysm has not been an entirely satisfactory surgical approach. The placement procedure may be arduous and lengthy because it often requires implanting multiple devices, such as coils, serially in the internal space of the aneurysm. Higher risks of complication from such sources as anesthesia, bleeding, thromboembolic events, procedural stroke, and infection are associated with such longer procedures. Moreover, because placement of structures in the internal space of an aneurysm does not generally completely occlude the opening, recanalization of the original aneurysm may occur, and debris and occlusive material may escape from within the aneurysm to create a risk of stroke or vessel blockage. Blood may also flow into the aneurysm and other blood vessel irregularities after the placement of embolic devices, which may increase the risks of complication and further enlargement of the aneurysm.


Despite the numerous conventional devices and systems available for implanting embolic materials in an aneurysm and for occluding physiological defects using minimally invasive techniques, these procedures remain risky and rarely restore the physiological structure to its normal, healthy condition. It is also challenging to position conventional implantable devices during deployment, prevent shifting or migration of such devices after deployment, and preserve blood flow in neighboring vessels following after deployment.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1A is an isometric view of an aneurysm device configured in accordance with an embodiment of the technology.



FIG. 1B is an isometric view of a closure structure portion of the aneurysm device of FIG. 1A.



FIG. 1C is a front view of the aneurysm device of FIG. 1A implanted at an aneurysm and configured in accordance with embodiments of the technology.



FIG. 2 is an isometric view of a closure structure portion of an aneurysm device configured in accordance with embodiments of the technology.



FIG. 3 is an isometric view of an aneurysm device configured in accordance with embodiments of the technology.



FIG. 4 is an isometric view of an aneurysm device configured in accordance with embodiments of the technology.



FIG. 5 is an isometric view of a closure structure portion of an aneurysm device configured in accordance with embodiments of the technology.



FIGS. 6A and 6B are isometric and front views, respectively, of a closure structure portion of an aneurysm device configured in accordance with embodiments of the technology.



FIG. 6C is a front view of the closure structure portion of FIGS. 6A and 6B implanted at an aneurysm in accordance with embodiments of the technology.



FIG. 7A is a front view of a closure structure portion of an aneurysm device configured in accordance with embodiments of the technology.



FIGS. 7B-7D are isometric views of the closure structure portion of FIG. 7A configured in accordance with embodiments of the technology.



FIG. 8A is an isometric view of an aneurysm device configured in accordance with embodiments of the technology.



FIGS. 8B and 8C are front views of the aneurysm device of FIG. 8A being placed at an aneurysm in accordance with embodiments of the technology.



FIG. 9 is an isometric view of a closure structure portion of an aneurysm device configured in accordance with embodiments of the technology.



FIGS. 10A and 10B are isometric and front views, respectively, of a closure structure portion of an aneurysm device configured in accordance with embodiments of the technology.



FIGS. 11A and 11B are isometric and top views, respectively, of a closure structure portion of an aneurysm device configured in accordance with embodiments of the technology.



FIGS. 12A and 12B are isometric and side views, respectively, of an aneurysm device configured in accordance with embodiments of the technology.



FIGS. 13A and 13B are top views an aneurysm device in an unassembled configuration in accordance with embodiments of the technology.





DETAILED DESCRIPTION

The present disclosure describes implantable therapeutic devices and methods for endovascular placement of devices at a target site, such as an opening at a neck of an aneurysm. In several embodiments, a therapeutic aneurysm device is endovascularly deliverable to a site proximate to an arterial aneurysm. The aneurysm device comprises a closure structure having a distal-facing aspect configured to at least partially occlude the aneurysm and a proximal-facing aspect configured to arch over lumina of an artery. The device further includes a supplemental stabilizer connected to the closure structure and configured to reside in the artery and press outward against a luminal wall thereof. In some embodiments, the device can also include a barrier spanning at least a portion of the distal-facing aspect of the closure structure and configured to further occlude a neck of the aneurysm.


The following description provides specific details for a thorough understanding of, and enabling description for, embodiments of the disclosure. Well-known structures, systems, and methods often associated with aneurysm treatment have not been shown or described in detail to avoid unnecessarily obscuring the description of the various embodiments of the disclosure. In addition, those of ordinary skill in the relevant art will understand that additional embodiments may be practiced without several of the details described below.



FIG. 1A is an isometric view of an aneurysm device 100 having a closure structure 110 and a support or supplemental stabilizer 120 configured in accordance with embodiments of the technology. FIG. 1B is an isometric view of the closure structure 110. Referring to FIGS. 1A and 1B together, the closure structure 110 can be a frame, scaffold, or other structure that at least partially occludes the neck of an aneurysm to prevent embolic coils or other coagulative material within the aneurysm from escaping into the bloodstream. The closure structure 110 comprises a plurality of scaffold struts or supports 130 (identified individually as struts 130a-130f). The struts 130 are joined together at corners 115, 116, and 117. The corners 115, 116, and 117 can be longitudinal corners that define the proximal end of the closure structure 110 that extends along the longitudinal axis L-L. The struts 130 can further include lateral corners 125, 126, and 127 defining a lateral aspect of the closure structure 110 that extends along the lateral axis T-T. The embodiment of the closure structure 110 illustrated in FIGS. 1A and 1B is generally symmetrical with respect to the centerlines of both the longitudinal L-L and the lateral T-T axes, but in other embodiments the closure structure 110 may have an asymmetrical configuration with respect to either or both of the longitudinal and lateral axes. Although the corners 125, 126, and 127 are illustrated as being rounded or looped, other embodiments of the corners may have a more pointed profile, a more complex curve, or other angular configurations. The struts 130 may be formed integrally with one another from a sheet of material, or separate struts may be formed and bonded together at the corners.


The closure structure 110 can define a distal framework portion, and the supplemental stabilizer 120 can define a proximal framework portion. Each of these portions can have one or more pairs of struts 130 (e.g., strut 130a is “paired” with strut 130f). In some embodiments, the struts 130 can curve inwardly toward the longitudinal axis L-L of the aneurysm device 100. The outline of the struts 130 is typically that of a quadrilateral form. In some embodiments, the struts 130 can have a rhombus-like configuration or diamond shape. In several embodiments, the struts 130 can bend to provide a tailored fit to a particular vasculature. In some embodiments, the struts 130 can bend or flexibly move independently of one another. For example, strut 130c may bend further into an aneurysm body than strut 130b. This independent adjustability can provide a customized fit to the particular contours of a given aneurysm, creating a more secure hold.


As discussed above, the struts 130 can be symmetrical (e.g., the same length along orthogonal axes) or asymmetrical in which one side of the rhombus-like structure can have an axis longer than the other side. Although many closure structures 110 described below have quadrilateral forms, the closure structures 110 are not limited to these shapes in that the distal-facing aspect of the distal framework portion may have other shapes, such as polygons or polygonal curvilinear shapes. In several embodiments, the rhombus-like supports 130 are concentric with a center at the longitudinal axis L-L of the aneurysm device 100. The lateral apices of the closure structure 102 are disposed at opposing ends of the lateral axis T-T of the distal framework portion. The two portions of the distal framework portion opposite each other across the longitudinal axis L-L may define lateral leaves of the distal framework portion.


In various embodiments, the closure structure 110 can be used in combination with the supplemental stabilizer 120 or independently from the supplemental stabilizer 120 at a neck of an aneurysm. The laterally-extending branches of the closure structure 110 and the supplemental stabilizer 120 hold the curved portion of the closure structure 110 at the neck of the aneurysm. However, in some embodiments, using the closure structure 110 independently of the supplemental stabilizer 120 can decrease the amount of contact the aneurysm device 100 has with a patient's vasculature. For example, in some embodiments, the closure structure 110 can be used independently of the supplemental stabilizer in the treatment of a ruptured aneurysm. In some embodiments, the supplemental stabilizer 120 can be used during placement of the closure structure 110, but then removed.



FIG. 1C is a front view of the aneurysm device of FIG. 1A in a deployed configuration and implanted at an aneurysm in accordance with embodiments of the technology. In the deployed configuration, the closure structure 110 has a distally projecting arch defined by a curved section of the distal framework portion. The supplemental stabilizer 120 extends proximally from the closure structure 110 at an angle relative to a lateral axis. A proximal-facing aspect of the arch of the closure structure 110 extends over the lumina of the bifurcating arteries. A distal-facing aspect of the arch of the closure structure 110 generally presses against the luminal surfaces of the bifurcating arteries. The distal-facing aspect of the closure structure 110 is configured to substantially align with or otherwise conform to the neck of the aneurysm by forming a curved surface that compatibly aligns with or engages the neck and the surrounding wall of the side branch vessels. In some embodiments, the distal-facing aspect has a complex curve, such as a hyperbolic paraboloid (e.g., a generally saddle-shaped form). In the illustrated embodiment, the hyperbolic paraboloid comprises a generally Y-shaped curve with a depressed central portion. The supplemental stabilizer 120 can have struts that extend down into the parent artery and press outwardly against the luminal surface thereof.


The distal-facing aspect or back of the proximal-facing surface generally aligns against the luminal surfaces of the bifurcating arteries, the sides of the arch extending down into the parent artery and aligned against the luminal surface thereof. The proximal face of the arch is generally and substantially transverse (perpendicular or orthogonal) to the lateral axis of the proximal framework. The arch spans unobtrusively over the lumina of the bifurcating arteries, forming no incursion into the vascular flow path. More particularly, the arch can be a non-enclosed opening or hole, but instead a structure entirely open in the proximal direction. In further embodiments, as will be discussed in more detail below, the closure structure 110 can include a cover or barrier portion spanning across one or more distal framework struts and configured to occlude the neck of the aneurysm.



FIG. 2 is an isometric view of a closure structure 210 of an aneurysm device configured in accordance with embodiments of the technology. The closure structure 210 has several features generally similar to the closure structure 110 described above with reference to FIGS. 1A-1C. The closure structure 210 further includes a barrier 240 spanning across a distal-facing aspect.


In the illustrated embodiment, the closure structure 210 includes perimeter struts 232 and curved inner arms 230 that meet the perimeter struts 232 at longitudinal corner points 217. The closure structure 210 is capable of temporary or permanent attachment to a supplemental stabilizer (such as the supplemental stabilizer 120 described above with reference to FIG. 1A) at the corner points 217. The inner arms 232 extend distally from the corner point 217, along a longitudinal midline L-L of the closure structure 210, and curve distally and laterally to an off-centered position. The inner arms 232 therefore allow the closure structure 210 and the barrier 240 to keep and maintain a shape in a deployed configuration and to fold up or compress in a spiral manner during delivery and/or removal.


The barrier 240 can be formed with or permanently or removably attached to the perimeter and inner arms 232, 230. The barrier 240 can comprise one or more permeable or semi-permeable membranes, covers, sheets, panels, mesh, or other structures that form an occlusive or semi-occlusive covering that (a) restricts, diverts, redirects, or inhibits vascular flow into the cavity of the aneurysm and/or (b) prevents materials from escaping the cavity. In this aspect, devices and methods of the described technology may provide repair and reconstruction of a blood vessel or a junction of blood vessels by placement and retention of the closure structure 210 across the neck of the aneurysm that diverts blood flow away from the aneurysm. Following placement and deployment, the barrier 240 may substantially cover the aneurysm neck and the closure structure 210 can form a structure that substantially conforms to the tissue surrounding the aneurysm and/or the neighboring vessel walls. The highly conforming fit generally restores the vascular anatomical neighborhood to a normal or more normal configuration, thereby supporting a normal vascular flow pattern and overall function. In the illustrated embodiments, the barrier 240 includes a barrier aperture 242 configured to provide access to the aneurysm (e.g., access for a catheter, access to deliver coils, etc.) As will be described in further detail below, the barrier 240 can comprise a single sheet or panel, or can comprise a plurality of sheets or panels layered and/or otherwise arranged on the device to achieve a desired barrier pattern and/or structure.



FIG. 3 is an isometric view of an aneurysm device 300 configured in accordance with embodiments of the technology. Generally similar to the aneurysm devices described above, the aneurysm device 300 includes a closure structure 310 and a supplemental stabilizer 320. The closure structure 310 comprises a plurality of nested, rhombus-shaped pairs of struts 330a-330c (collectively struts, 330). A barrier 340 spans the struts 330 and includes a central hole or slit 342 at a central portion of the closure structure 310, within the innermost set of struts 330a.



FIG. 4 is an isometric view of an aneurysm device 400 configured in accordance with embodiments of the technology. Generally similar to the aneurysm device 300 described above with reference to FIG. 3, the aneurysm device 400 includes a closure structure 410 and a supplemental stabilizer 420. The closure structure 410 comprises a plurality struts 430a-430c (collectively struts, 430) forming nested rhombus shapes. In this embodiment, however, a barrier 440 spans only the space between the innermost struts 330a and the middle struts 330b.


The illustrated configurations are merely representative of the numerous arrangements the struts 430 and barrier 440 could take. For example, there could be more or fewer than three sets of nested struts 430, and the barrier 440 could cover more or fewer areas or parts of areas between the struts 430. In some embodiments, the degree of barrier coverage across the struts can be selected based on a desired degree of occlusion, type or characteristics of the aneurysm, and/or desired access to the body of the aneurysm.



FIG. 5 is an isometric view of a closure structure portion 510 of an aneurysm device configured in accordance with embodiments of the technology. The closure structure 510 has several features generally similar to the closure structure 210 described above with reference to FIG. 2. For example, the closure structure 510 has a barrier 540 spanning across perimeter struts 532 and curved inner arms 530. The barrier 540 includes an optional access aperture 542.


The closure structure 510 further includes flexible anchor legs 552 distally coupled to the perimeter struts 530. While two legs 552 are shown descending from the illustrated side of the closure structure 510, there can be more or fewer legs 552, of the same or different dimensions, in further embodiments of the technology. The anchor legs 552 can provide pivotable movement (or shock absorption) between the closure structure 610 and a supplemental stabilizer, such as the supplemental stabilizer 120 described above with reference to FIG. 1A. The anchor legs 552 can comprise springs, hinges, or other movable or flexible structures that would allow movement of the closure structure 510 relative to a supplemental stabilizer.



FIGS. 6A and 6B are isometric and front views, respectively, of a closure structure 610 having several features generally similar to the closure structures described above. FIG. 6C is a front view of the closure structure 610 at an aneurysm in accordance with embodiments of the technology. Referring to FIGS. 6A-6C together, the closure structure 610 includes a barrier 640 spanning distal arms 630. The closure structure 610 further includes proximal arms 660 coupled to the distal arms 630 via a midline strut 662. In the illustrated embodiment, the midline strut 662 extends distally from a distal arm junction point 617. The barrier 640 can include an aperture 642 therein.


In several embodiments, at least one of the distal arms 630 or proximal arms 660 are curved or parabolic shaped to better conform to the shape of the aneurysm or the vasculature to provide the desired degree of aneurysm occlusion and device stability. For example, in the illustrated embodiment, the distal arms 630 extend distally but have a lateral, proximally-dipping curve, while the proximal arms 660 have an approximately 180-degree distal curve before projecting laterally. As best shown in FIG. 6C, the distal arms 630 can be placed within the aneurysm and can conform against the aneurysm wall, while the proximal arms 660 can conform against the luminal wall outside of the aneurysm.



FIG. 7A is a front view of a closure structure 710 configured in accordance with embodiments of the technology. FIGS. 7B-7D are isometric views of the closure structure 710. Referring to FIGS. 7A to 7D together, the closure structure 710 includes multiple sets of nested, generally triangular-shaped baffles or panels 730a-730c (collectively panels 730). Each panel 730 comprises a strut framework and sheets or panels of barrier 740a-740c (collectively barrier 740). Pairs of panels 730 join at junctions 717a-717c on a central stem.


The panels 730 can be individually covered by the barrier 740, or pairs of struts (e.g., forming a V-shape) can be covered. One or more panels 730 can include an opening or hole 742. For example, in the illustrated embodiment, the closure structure 710 includes a central hole 742 that extends longitudinally through each pair of adjacent panels 730, thereby providing access from a proximal side of the closure structure 710 to the interior of the aneurysm. While the panels 730 are discussed as triangles, in further embodiments the panels 730 can be shaped as rectangles, circles, squares, or other polygonal or curved shapes. The panels 730 can laterally overlap and can be used to control, contain, and/or divert flow. The panels 730 can function as baffles that can pivotably bend or otherwise move relative to one another to adjust from an open state to a closed state. In various embodiments of use, one or more of the panels 730 can be inside the aneurysm while other panels 730 can be outside the aneurysm. In further embodiments, all of the panels 730 can be inside or outside the aneurysm.



FIG. 8A is an isometric view of an aneurysm device 800 configured in accordance with embodiments of the technology. The aneurysm device 800 includes a closure structure 810 and a supplemental stabilizer 820. The closure structure 810 includes one or more rhombus-shaped sets of struts 830a, 830b (collectively struts 830), generally similar to the closure structures described above. The closure structure 810 further includes distally-extending anchor arms 838. In the illustrated embodiment, the struts 830 are curved distally and laterally, in some embodiments extending laterally beyond the anchor arms 838.



FIGS. 8B and 8C are front views of the aneurysm device of FIG. 8A being placed at an aneurysm in accordance with embodiments of the technology. The struts 830 are configured to curve against the exterior neck of the aneurysm. In further embodiments, one or more of the struts 830 can be placed within the aneurysm. The anchor struts 838 can be located within the side walls of the aneurysm and can provide improved fit/conformability to the aneurysm neck. As shown in FIG. 8C, in some embodiments, the supplemental stabilizer 820 can be removed upon stable placement of the closure structure 810 or can be not used at all.



FIG. 9 is an isometric view of a closure structure portion 910 of an aneurysm device configured in accordance with further embodiments of the technology. Having features generally similar to several of the closure structures described above, the closure structure 910 includes inner, middle, and outer sets of struts (numbered 930a-930c, respectively). In the illustrated embodiment, the inner struts 930a expand or bend distally upward from the laterally-joined middle and outer struts 903b, 903c. This bendability provides a niche between the inner 930a and middle 930b struts. In use, the niche can be used to clip into or otherwise engage the tissue proximate to the aneurysm.



FIGS. 10A and 10B are isometric and front views, respectively, of a closure structure 1010 configured in accordance with embodiments of the technology. The closure structure 1010 includes an inner set of struts 1030a and an outer set of struts 1030b. In some embodiments, the inner set of struts 1030a can be bent or formed in a direction offset from the outer set of struts 1030b to “expand” the aneurysm device 300. In some embodiments, the inner set of struts 1030a can be placed in an aneurysm and the outer set of struts 330b can be placed outside the aneurysm to anchor or stabilize the closure structure 1010 (e.g., to clip the aneurysm device into the aneurysm).



FIGS. 11A and 11B are isometric and top views, respectively, of a closure structure 1110 configured in accordance with embodiments of the technology. The closure structure 1110 includes an inner set of struts 1130a and an outer set of struts 1130b. In some embodiments, the inner set of struts 1130a can be bent or formed in a direction offset from the outer set of struts 1130b. In some embodiments, the inner set of struts 1130a can be placed in an aneurysm and the outer set of struts 1130b can be placed outside the aneurysm for anchoring the closure structure 1110.



FIGS. 12A and 12B are isometric and side views, respectively, of an aneurysm device 1200 configured in accordance with embodiments of the technology. The aneurysm device 1200 includes a closure structure 1210 and a supplemental stabilizer 1220. The closure structure 1210 includes sets of struts 1230a-1230c (collectively, struts 1230) arranged in triangular or rhombus configurations and extending laterally from a midline of the device 1200. As described in several embodiments above, the sets of struts 1230 can rest in or outside an aneurysm, or can sandwich or clip onto the neck of the aneurysm. In the illustrated embodiment, the supplemental stabilizer 1220 includes ring-shaped anchors 1222 extending proximally from the closure structure 1210. These anchors 1222 can be configured to press against vascular walls to provide device stability without blocking blood flow.



FIGS. 13A and 13B are top views an aneurysm device 1300 in an unassembled configuration in accordance with embodiments of the technology. Referring to FIGS. 13A and 13B together, the aneurysm device 1300 is constructed from a substantially flat substrate by cutting, etching, stamping, or otherwise forming the framework of the closure structure 1310 and the unassembled supplemental stabilizer 1320. In several embodiments, the device 1300 can be cut from a single piece of substrate. For example, the closure structure 1310 (including sets of struts 1330a-1330c) and the supplemental stabilizer 1320 can be constructed from a flat sheet of material having substantially uniform thickness. In other embodiments different regions of the sheeted material can have different thicknesses corresponding to the desired thickness for portions of the closure structure 1310 and/or the supplemental stabilizer 1320.


The closure structure 1310 can be folded or bent into a curve along the lateral axis T-T such that the portions of the closure structure 1310 associated with corners 1317a-1317c define paired longitudinally aligned structures on either side and generally substantially orthogonal to the lateral axis T-T. The paired longitudinally aligned structures can be substantially parallel to each other and define anchors that hold the closure structure 1310 in place. The closure structure 1310 forms a vertex that is resiliently bent by a total of about 180° and is biased outward. The outward bias of the closure structure 1310 is due to the materials that form the closure structure, such as resilient metals or alloys including Nitinol and other shape memory metals. The outward biasing force is conveyed to the supplemental stabilizer 1320 from the closure structure 1310 such that the supplemental stabilizer 1320 presses outward against the lumen of a parent vessel that extends at an angle relative to the lengthwise dimension of the closure structure 1310.


Radiopaque markers 1372, 1374, 1376, and 1378 or radiopaque compounds may be associated with certain structures or portions of the device structure to facilitate accurate positioning, placement and monitoring of the deployed device in the vasculature. In one embodiment, for example, a radiopaque composition may be incorporated in the closure structure or provided as a coating on the closure structure. Variations in the marker geometry may be adopted to distinguish different segments of the device framework. For example, the proximal legs of the device may incorporate a marker with two dots, while the portion of the device closer to or in proximity to the covering may incorporate a single dot. Alternatively, different shaped markers may be used to differentiate different parts of the device. Radiopaque markers may be added anywhere along the device frame or attached materials, coverings, and membranes to provide spatial location of different device components and features under angiography. In several embodiments, for example, radiopaque markers can be added to laterally and/or longitudinally asymmetric points on the closure structure 1310 and/or supplemental stabilizer 1320 (i.e., asymmetric with reference to the lateral axis T-T, longitudinal axis L-L, or a center point 1370 at the intersection of the longitudinal and lateral axes). In the embodiment illustrated in FIG. 13A, markers 1372, 1374, 1376, and 1378 are offset from the longitudinal axis L-L. Marker 1372 is offset by distance X4, marker 1374 is offset by distance X2, marker 1376 is offset by distance X1, and marker 1378 is offset by distance X3, where Xi, X2, X3, and X4 are all unequal distances. By placing these markers asymmetrically, the markers do not overlap when the device is folded or compressed during placement. The device 1300 is therefore less bulky for delivery.


From the foregoing, it will be appreciated that specific embodiments of the disclosure have been described herein for purposes of illustration, but that various modifications may be made without deviating from the spirit and scope of the disclosure. For example, structures (such as supplemental stabilizers and/or barriers) and/or processes described in the context of particular embodiments may be combined or eliminated in other embodiments. In particular, the aneurysm devices described above with reference to particular embodiments can include one or more additional features or components, or one or more of the features described above can be omitted. Moreover, while advantages associated with certain embodiments of the disclosure have been described in the context of these embodiments, other embodiments may also exhibit such advantages, and not all embodiments need necessarily exhibit such advantages to fall within the scope of the disclosure.

Claims
  • 1. An aneurysm enclosure framework in a planar configuration prior to assembly into a deliverable configuration, the aneurysm enclosure framework comprising: a central framework portion and two support framework portions, the support framework portions connected to opposite sides of the central framework portion, the central and support framework portions aligned along a longitudinal axis,wherein the central framework portion comprises a set of central struts forming at least one quadrilateral form with first and second longitudinal junctions joining the struts at two longitudinal apices, and two lateral junctions joining the struts at apices of a lateral axis; anda radiopaque composition incorporated in a laterally asymmetric pattern on the central framework portion.
  • 2. The aneurysm enclosure framework of claim 1 wherein the radiopaque composition is coated on the closure structure.
  • 3. The aneurysm enclosure framework of claim 1 wherein the radiopaque composition is dotted on the closure structure.
  • 4. The aneurysm enclosure framework of claim 1 wherein the radiopaque composition is incorporated in a laterally and longitudinally asymmetric pattern on the closure structure.
  • 5. The aneurysm enclosure framework of claim 1 wherein the radiopaque composition is further incorporated in a laterally asymmetric pattern on the support framework.
  • 6. The aneurysm enclosure framework of claim 1 wherein the asymmetric pattern comprises radiopaque markings having different shapes or sizes.
CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a divisional of U.S. patent application Ser. No. 14/808,343, filed on Jul. 24, 2015 and entitled DEVICES, SYSTEMS AND METHODS FOR ENCLOSING AN ANATOMICAL OPENING, which in turn is a divisional of U.S. patent application Ser. No. 13/646,602, now U.S. Pat. No. 9,119,625, filed on Oct. 5, 2012 and entitled DEVICES, SYSTEMS AND METHODS FOR ENCLOSING AN ANATOMICAL OPENING, which claims the benefit of U.S. Provisional Application No. 61/543,785, filed on Oct. 5, 2011 and entitled DEVICES, SYSTEMS AND METHODS FOR ENCLOSING AN ANATOMICAL OPENING, all of which are incorporated herein by reference in their entireties.

US Referenced Citations (296)
Number Name Date Kind
3868956 Alfidi et al. Mar 1975 A
4164045 Bokros et al. Aug 1979 A
4248234 Assenza et al. Feb 1981 A
4645495 Vaillancourt Feb 1987 A
4651751 Swendson et al. Mar 1987 A
4665906 Jervis May 1987 A
4706671 Weinrib Nov 1987 A
4710192 Liotta et al. Dec 1987 A
4739768 Engelson Apr 1988 A
4820298 Leveen et al. Apr 1989 A
4873978 Ginsburg Oct 1989 A
4909787 Danforth Mar 1990 A
4994069 Ritchart et al. Feb 1991 A
5011488 Ginsburg Apr 1991 A
5074869 Daicoff Dec 1991 A
5122136 Guglielmi et al. Jun 1992 A
5226911 Chee et al. Jul 1993 A
5250071 Palermo Oct 1993 A
5261916 Engelson Nov 1993 A
5263964 Purdy Nov 1993 A
5263974 Matsutani et al. Nov 1993 A
5271414 Partika et al. Dec 1993 A
5304195 Twyford, Jr. et al. Apr 1994 A
5334168 Hemmer Aug 1994 A
5342386 Trotta Aug 1994 A
5350397 Palermo et al. Sep 1994 A
5354295 Guglielmi et al. Oct 1994 A
5527338 Purdy Jun 1996 A
5531685 Hemmer et al. Jul 1996 A
5578074 Mirigian Nov 1996 A
5624449 Pham et al. Apr 1997 A
5643254 Scheldrup et al. Jul 1997 A
5665106 Hammerslag Sep 1997 A
5669931 Kupiecki et al. Sep 1997 A
5693067 Purdy Dec 1997 A
5733294 Forber et al. Mar 1998 A
5733329 Wallace et al. Mar 1998 A
5749890 Shaknovich May 1998 A
5749894 Engelson May 1998 A
5759194 Hammerslag Jun 1998 A
5766192 Zacca Jun 1998 A
5769884 Solovay Jun 1998 A
5797953 Tekulve Aug 1998 A
5814062 Sepetka et al. Sep 1998 A
5843103 Wulfman Dec 1998 A
D407818 Mariant et al. Apr 1999 S
5895391 Farnholtz Apr 1999 A
5895410 Forber et al. Apr 1999 A
5910145 Fischell et al. Jun 1999 A
5911737 Lee et al. Jun 1999 A
5916235 Guglielmi Jun 1999 A
5925060 Forber Jul 1999 A
5925062 Purdy Jul 1999 A
5925683 Park Jul 1999 A
5928260 Chin et al. Jul 1999 A
5933329 Tijanoc et al. Aug 1999 A
5935114 Jang et al. Aug 1999 A
5935148 Villar et al. Aug 1999 A
5951599 McCrory Sep 1999 A
5968068 Dehdashtian et al. Oct 1999 A
5980514 Kupiecki et al. Nov 1999 A
5980554 Lenker et al. Nov 1999 A
5984944 Forber Nov 1999 A
6007544 Kim Dec 1999 A
6013055 Bampos et al. Jan 2000 A
6022341 Lentz Feb 2000 A
6036720 Abrams et al. Mar 2000 A
6063070 Eder May 2000 A
6063104 Villar et al. May 2000 A
6071263 Kirkman Jun 2000 A
6077291 Das Jun 2000 A
6081263 LeGall et al. Jun 2000 A
6090125 Horton Jul 2000 A
6093199 Brown et al. Jul 2000 A
6096021 Helm et al. Aug 2000 A
6096034 Kupiecki et al. Aug 2000 A
6102917 Maitland et al. Aug 2000 A
6110191 Dehdashtian et al. Aug 2000 A
6117157 Tekulve Sep 2000 A
6139564 Teoh Oct 2000 A
6146339 Biagtan et al. Nov 2000 A
6152944 Holman et al. Nov 2000 A
6168615 Ken et al. Jan 2001 B1
6168622 Mazzocchi Jan 2001 B1
6174322 Schneidt Jan 2001 B1
6183495 Lenker et al. Feb 2001 B1
6193708 Ken et al. Feb 2001 B1
RE37117 Palermo Mar 2001 E
6221066 Ferrera et al. Apr 2001 B1
6221086 Forber Apr 2001 B1
6224610 Ferrera May 2001 B1
6228052 Pohndorf May 2001 B1
6261305 Marotta et al. Jul 2001 B1
6293960 Ken Sep 2001 B1
6296622 Kurz et al. Oct 2001 B1
6309367 Boock Oct 2001 B1
6325807 Que Dec 2001 B1
6344041 Kupiecki et al. Feb 2002 B1
6344048 Chin et al. Feb 2002 B1
6361558 Hieshima et al. Mar 2002 B1
6375668 Gifford et al. Apr 2002 B1
6383174 Eder May 2002 B1
6398791 Que et al. Jun 2002 B1
6478773 Gandhi et al. Nov 2002 B1
6491711 Durcan Dec 2002 B1
6517515 Eidenschink Feb 2003 B1
6530935 Wensel et al. Mar 2003 B2
6533905 Johnson et al. Mar 2003 B2
6554794 Mueller et al. Apr 2003 B1
6589256 Forber Jul 2003 B2
6592605 Lenker et al. Jul 2003 B2
6613074 Mitelberg et al. Sep 2003 B1
6616681 Hanson et al. Sep 2003 B2
6626889 Simpson et al. Sep 2003 B1
6626928 Raymond et al. Sep 2003 B1
6638268 Niazi Oct 2003 B2
6652556 VanTassel et al. Nov 2003 B1
6663607 Slaikeu et al. Dec 2003 B2
6663648 Trotta Dec 2003 B1
6669795 Johnson et al. Dec 2003 B2
6672338 Esashi et al. Jan 2004 B1
6679836 Couvillon, Jr. Jan 2004 B2
6679903 Kurz Jan 2004 B2
6689141 Ferrera et al. Feb 2004 B2
6694979 Deem et al. Feb 2004 B2
6723112 Ho et al. Apr 2004 B2
6740073 Saville May 2004 B1
6740277 Howell et al. May 2004 B2
6746468 Sepetka et al. Jun 2004 B1
6780196 Chin et al. Aug 2004 B2
6790218 Jayaraman Sep 2004 B2
6802851 Jones et al. Oct 2004 B2
6811560 Jones et al. Nov 2004 B2
6824553 Samson et al. Nov 2004 B1
6835185 Ramzipoor et al. Dec 2004 B2
6837870 Duchamp Jan 2005 B2
6843802 Villalobos et al. Jan 2005 B1
6855153 Saadat Feb 2005 B2
6863678 Lee et al. Mar 2005 B2
6890218 Patwardhan et al. May 2005 B2
6911037 Gainor et al. Jun 2005 B2
6936055 Ken et al. Aug 2005 B1
6939055 Durrant et al. Sep 2005 B2
6986774 Middleman et al. Jan 2006 B2
6994092 van der Burg et al. Feb 2006 B2
7011094 Rapacki et al. Mar 2006 B2
7033374 Schaefer et al. Apr 2006 B2
7033387 Zadno-Azizi et al. Apr 2006 B2
7122043 Greenhalgh et al. Oct 2006 B2
7147659 Jones Dec 2006 B2
7156871 Jones et al. Jan 2007 B2
7169177 Obara Jan 2007 B2
7229461 Chin et al. Jun 2007 B2
7232461 Ramer Jun 2007 B2
7267679 McGuckin, Jr. et al. Sep 2007 B2
7306622 Jones et al. Dec 2007 B2
7322960 Yamamoto et al. Jan 2008 B2
7343856 Blohdorn Mar 2008 B2
7387629 Vanney et al. Jun 2008 B2
7410482 Murphy et al. Aug 2008 B2
7569066 Gerberding et al. Aug 2009 B2
7608088 Jones et al. Oct 2009 B2
7662168 McGuckin, Jr. et al. Feb 2010 B2
7857825 Moran et al. Dec 2010 B2
7892254 Klint et al. Feb 2011 B2
8016853 Griffen et al. Sep 2011 B2
8075585 Lee et al. Dec 2011 B2
8187315 Clauson et al. May 2012 B1
8262692 Rudakov Sep 2012 B2
8388650 Gerberding et al. Mar 2013 B2
8444667 Porter May 2013 B2
8470013 Duggal et al. Jun 2013 B2
8540763 Jones et al. Sep 2013 B2
8545530 Eskridge et al. Oct 2013 B2
8551132 Eskridge et al. Oct 2013 B2
8556953 Berez et al. Oct 2013 B2
8715312 Burke et al. May 2014 B2
8715338 Frid May 2014 B2
8728141 Riina et al. May 2014 B2
8747430 Porter Jun 2014 B2
8771341 Strauss et al. Jul 2014 B2
8915950 Cam et al. Dec 2014 B2
8926680 Ferrera et al. Jan 2015 B2
8956399 Cam et al. Feb 2015 B2
8979893 Gerberding et al. Mar 2015 B2
9060886 Molaei et al. Jun 2015 B2
9107670 Hannes et al. Aug 2015 B2
9119625 Bachman et al. Sep 2015 B2
9179918 Levy et al. Nov 2015 B2
9186267 Losordo et al. Nov 2015 B2
9192388 Cam et al. Nov 2015 B2
9211124 Campbell et al. Dec 2015 B2
9259229 Abrams et al. Feb 2016 B2
9277924 Clarke et al. Mar 2016 B2
20020026232 Marotta et al. Feb 2002 A1
20030033003 Harrison et al. Feb 2003 A1
20030057156 Peterson et al. Mar 2003 A1
20030139802 Wulfman et al. Jul 2003 A1
20030181922 Alferness Sep 2003 A1
20030181942 Sutton et al. Sep 2003 A1
20030195385 DeVore Oct 2003 A1
20030195553 Wallace et al. Oct 2003 A1
20030212412 Dillard et al. Nov 2003 A1
20040044391 Porter Mar 2004 A1
20040068314 Jones et al. Apr 2004 A1
20040087998 Lee et al. May 2004 A1
20040111112 Hoffmann Jun 2004 A1
20040158311 Berhow et al. Aug 2004 A1
20040167597 Costantino et al. Aug 2004 A1
20040167602 Fischell et al. Aug 2004 A1
20040172056 Guterman et al. Sep 2004 A1
20040193246 Ferrera Sep 2004 A1
20040210248 Gordon et al. Oct 2004 A1
20040210298 Rabkin et al. Oct 2004 A1
20050021023 Guglielmi et al. Jan 2005 A1
20050025797 Wang et al. Feb 2005 A1
20050033409 Burke et al. Feb 2005 A1
20050096728 Ramer May 2005 A1
20050177224 Fogarty et al. Aug 2005 A1
20060004436 Amarant et al. Jan 2006 A1
20060030929 Musbach Feb 2006 A1
20060052862 Kanamaru et al. Mar 2006 A1
20060058837 Bose et al. Mar 2006 A1
20060064151 Guterman et al. Mar 2006 A1
20060106418 Seibold et al. May 2006 A1
20060200234 Hines Sep 2006 A1
20060206199 Churchwell et al. Sep 2006 A1
20060247680 Amplatz et al. Nov 2006 A1
20060259131 Molaei et al. Nov 2006 A1
20060264905 Eskridge et al. Nov 2006 A1
20060264907 Eskridge et al. Nov 2006 A1
20070067015 Jones et al. Mar 2007 A1
20070088387 Eskridge et al. Apr 2007 A1
20070106311 Wallace et al. May 2007 A1
20070191884 Eskridge et al. Aug 2007 A1
20070198075 Levy Aug 2007 A1
20070203567 Levy Aug 2007 A1
20070270902 Slazas et al. Nov 2007 A1
20080004653 Sherman et al. Jan 2008 A1
20080004692 Henson et al. Jan 2008 A1
20080039930 Jones et al. Feb 2008 A1
20080147100 Wallace Jun 2008 A1
20080183143 Palasis et al. Jul 2008 A1
20080221600 Dieck et al. Sep 2008 A1
20080269774 Garcia et al. Oct 2008 A1
20080319533 Lehe Dec 2008 A1
20090069880 Vonderwalde et al. Mar 2009 A1
20090125053 Ferrera et al. May 2009 A1
20090306678 Hardert et al. Dec 2009 A1
20100023105 Levy et al. Jan 2010 A1
20100063531 Rudakov et al. Mar 2010 A1
20100094335 Gerberding et al. Apr 2010 A1
20110022149 Cox et al. Jan 2011 A1
20110270373 Sampognaro et al. Nov 2011 A1
20120143237 Cam et al. Jun 2012 A1
20120143317 Cam et al. Jun 2012 A1
20120245674 Molaei et al. Sep 2012 A1
20120290067 Cam et al. Nov 2012 A1
20120296361 Cam et al. Nov 2012 A1
20130090682 Bachman et al. Apr 2013 A1
20130204290 Clarke et al. Aug 2013 A1
20130268046 Gerberding et al. Oct 2013 A1
20130268053 Molaei et al. Oct 2013 A1
20130274862 Cox et al. Oct 2013 A1
20130274863 Cox et al. Oct 2013 A1
20130274866 Cox et al. Oct 2013 A1
20130274868 Cox et al. Oct 2013 A1
20130304109 Abrams et al. Nov 2013 A1
20140052233 Cox et al. Feb 2014 A1
20140058420 Hannes et al. Feb 2014 A1
20140121752 Losordo et al. May 2014 A1
20140128901 Kang et al. May 2014 A1
20140142608 Eskridge et al. May 2014 A1
20140180377 Bose et al. Jun 2014 A1
20140236216 Gerberding Aug 2014 A1
20150039015 Gerberding Feb 2015 A1
20150142025 Brandeis May 2015 A1
20150142042 Cox May 2015 A1
20150142043 Furey May 2015 A1
20150157329 Rudakov et al. Jun 2015 A1
20150157331 Levy et al. Jun 2015 A1
20150164512 Chin et al. Jun 2015 A1
20150164665 Cam et al. Jun 2015 A1
20150182361 Ferrera et al. Jul 2015 A1
20150196305 Meyer et al. Jul 2015 A1
20150216534 Riina et al. Aug 2015 A1
20150216687 Gerberding et al. Aug 2015 A1
20150245932 Molaei et al. Sep 2015 A1
20150250628 Monstadt et al. Sep 2015 A1
20150282962 Strauss et al. Oct 2015 A1
20150342612 Wu et al. Dec 2015 A1
20160015395 Molaei et al. Jan 2016 A1
20160015396 Cox et al. Jan 2016 A1
20160030050 Franano et al. Feb 2016 A1
20160038153 Losordo et al. Feb 2016 A1
20160249936 Clarke et al. Sep 2016 A1
Foreign Referenced Citations (63)
Number Date Country
2006304660 Apr 2007 AU
1384726 Dec 2002 CN
1399530 Feb 2003 CN
1399531 Feb 2003 CN
101489492 Jul 2009 CN
102202585 Sep 2011 CN
102762156 Oct 2012 CN
103230290 Aug 2013 CN
103381101 Nov 2013 CN
103582460 Feb 2014 CN
103607964 Feb 2014 CN
102008028308 Apr 2009 DE
0820726 Jan 1998 EP
00996372 May 2000 EP
1269935 Jan 2003 EP
1527753 May 2005 EP
1951129 Aug 2008 EP
2326259 Jun 2011 EP
2451363 May 2012 EP
2713904 Apr 2014 EP
2713905 Apr 2014 EP
1134421 Mar 2014 HK
2001286478 Oct 2001 JP
2002516705 Jun 2002 JP
2003512129 Apr 2003 JP
2005522266 Jul 2005 JP
2009512515 Mar 2009 JP
2013226419 Nov 2013 JP
20080081899 Sep 2008 KR
9724978 Jul 1997 WO
9726939 Jul 1997 WO
9731672 Sep 1997 WO
9823227 Jun 1998 WO
9850102 Nov 1998 WO
9905977 Feb 1999 WO
9907294 Feb 1999 WO
9915225 Apr 1999 WO
0013593 Mar 2000 WO
0130266 May 2001 WO
2001093782 Dec 2001 WO
2002000139 Jan 2002 WO
0213899 Feb 2002 WO
02071977 Sep 2002 WO
02078777 Oct 2002 WO
02087690 Nov 2002 WO
03059176 Jul 2003 WO
03075793 Sep 2003 WO
2004019790 Mar 2004 WO
2004026149 Apr 2004 WO
2004105599 Dec 2004 WO
05033409 Apr 2005 WO
2005082279 Sep 2005 WO
2006119422 Nov 2006 WO
2007047851 Apr 2007 WO
2008151204 Dec 2008 WO
2010028314 Mar 2010 WO
2011029063 Mar 2011 WO
2012167137 Dec 2012 WO
2012167150 Dec 2012 WO
2012167156 Dec 2012 WO
2013169380 Nov 2013 WO
2014029835 Feb 2014 WO
2015179377 Nov 2015 WO
Non-Patent Literature Citations (18)
Entry
Polytetraflouroethylene Implants, DermNet NZ, Nov. 11, 2005, http://dermetnz.org/polytetrafluoroethylene.html.
International Search Report for International Application No. PCT/US06/40907, dated May 1, 2008, 2 pages.
Extended European Search Report, European Application No. 06826291.4, dated Nov. 19, 2009, 7 pages.
Singapore Examination Report for Singapore Application No. 200802811-0, dated Jul. 12, 2009, 7 pages.
International Search Report and Written Opinion for International Application No. PCT/US2009/056133, dated Oct. 26, 2009, 11 pages.
Micrus Copr.; “Concurse 14 Microcatheter” Product Brochure; Sunnyvale ,CA, USA.
Cordis NeuroVascular, Inc.; “Masstransit Microcatheter,” Product Brochure; No. 153-8383-3; Miami Lakes, FL, USA (2003).
Cordis NeuroVascular, Inc.; “Prolwer Select Plus Microcatheter,” Product Brochure; No. 154-9877-1; Miami Lakes, FL, USA (2003).
Cordis NeuroVascular, Inc.; “Rapid Transit Microcatheter,” Product Brochure; No. 152-7369-2; Miami Lakes, FL, USA (2003).
Cordis NeuroVascular, Inc.; “Prowler Select LP Microcatheter,” Product Brochure; No. 155-5585; Miami Lakes, FL, USA (2004).
Gupta et al. SMST-2003: Proc. Intl. Conf. Shape Memory Superelastic Technol.; Pacific Grove, CA; p. 639; 2003.
International Search Report and Written Opinion for Application No. PCT/US2010/047908, dated May 25, 2011.
International Search Report and Written Opinion for International Application No. PCT/US2010/047908, dated Mar. 15, 2012, 11 pages.
International Search Report and Written Opinion for International Application PCT/US2012/040536, dated Oct. 15, 2012, 17 pages.
International Search Report and Written Opinion for International Application No. PCT/US2012/040552, dated Aug. 28, 2012, 14 pages.
International Search Report and Written Opinion for International Application PCT/US2012/040558, dated Oct. 8, 2012, 17 pages.
International Search Report and Written Opinion for International Application PCT/US2012/059133, dated Mar. 11, 2013,15 pages.
International Search Report and Written Opinion for International Application PCT/US2013/031793, dated Jun. 26, 2013, 14 pages.
Related Publications (1)
Number Date Country
20170224353 A1 Aug 2017 US
Provisional Applications (1)
Number Date Country
61543785 Oct 2011 US
Divisions (2)
Number Date Country
Parent 14808343 Jul 2015 US
Child 15496657 US
Parent 13646602 Oct 2012 US
Child 14808343 US